Latest News

Efficacy of Second-Line Oxaliplatin, Leucovorin, and Fluorouracil in Patients With Gemcitabine-Refractory Pancreatic Cancer

Efficacy of Second-Line Oxaliplatin, Leucovorin, and Fluorouracil in Patients With Gemcitabine-Refractory Pancreatic Cancer

According to a new study published in the Journal of Clinical Oncology, second-line oxaliplatin, leucovorin (folinic acid), and fluorouracil (5-FU) (OFF) significantly increased overall survival compared with leucovorin and 5-FU (FF) for advanced pancreatic cancer.

Vitamin D Deficiency Worsens Diffuse B-Cell Lymphoma Outcomes

Vitamin D Deficiency Worsens Diffuse B-Cell Lymphoma Outcomes

Deficiency impairs rituximab-mediated cellular cytotoxicity; substitution improves RMCC.

Hodgkin's Lymphoma Survivors Face Higher Diabetes Risk

Hodgkin's Lymphoma Survivors Face Higher Diabetes Risk

Para-aortic radiation with ≥36 Gy linked to increased risk of diabetes mellitus.

Xalkori To Be Tested With Investigational Pembrolizumab To Treat Lung Cancer

Xalkori To Be Tested With Investigational Pembrolizumab To Treat Lung Cancer

Pfizer will test Xalkori in hopes the combination will improve the outcomes for lung cancer patients.

Leukemia Treatment Could Involve Drugs That Block DNA Repair Defects

Leukemia Treatment Could Involve Drugs That Block DNA Repair Defects

A drug originally designed for killing a limited type of cancer cells could potentially be used to treat leukaemia.

More News

Health Care Expenditure Slowed in US

Health sector prices explain much of difference between U.S. and other high-spending countries.

States Concerned About Higher-Than-Expected Medicaid Enrollment

Millions signing up for Medicaid to comply with federal health care law.

EHR Use More Than Doubles

Almost 80% of doctors in the United States have switched from paper to electronic health records.

Many Docs Order Unnecessary Medical Tests

Most physicians believe that doctors order too many medical tests, yet half admit to doing so themselves in response to a patient who insists, a new survey shows.

Reducing Six Risk Factors May Prevent 37 Million Deaths

Several modifiable risk factors can cut chronic disease deaths over the next 15 years.

Majority of Women Lack Accurate Knowledge of Their Own Breast Cancer Risk

Caucasian women overestimate their risk of breast cancer while African American and Hispanic women underestimate their risk, according to research presented at BCS 2013.

Survey Identifies Modifiable Barriers to Mammography Screening Among Rural US Women

A survey presented at BCS 2013 has found a number of factors that cause rural US women to avoid breast cancer screening.

Perioperative MRI of Uncertain Benefit for Women with DCIS

The benefit of perioperative MRI for women with ductal carcinoma in situ (DCIS) is "uncertain," found a study presented during BCS 2013.

Dr. Edith Perez's Recommended Abstracts at BCS 2013

ChemotherapyAdvisor.com Editorial Board member Dr. Edith Perez of the Mayo Clinic, Jacksonville, FL, recommends high impact abstracts at the Breast Cancer Symposium 2013.

Radiotherapy for DCIS Is Not Associated With Increased Cardiovascular Disease

Women who underwent radiation for ductal carcinoma in situ do not face an increased risk of cardiovascular disease, found a study presented at BCS 2013.

Mental Illness Develops in 20% of Elderly Prostate Cancer Patients

Risk is greater in patients managed with watchful waiting than in those who undergo radical treatment.

High CRP Predicts Poor RCC-Specific Survival in Hemodialysis Patients

Study shows a 3.5 times increased risk of death from renal cancer in hemodialysis patients undergoing nephrectomy.

Focal Prostate Cancer Therapy Safe, Feasible

In a study, none of the 62 men who had the treatment experienced erectile dysfunction or urinary incontinence.

MRI Highly Accurate in Detecting Significant Prostate Cancer

Diffusion-weighted technique found to have a sensitivity and specificity of 89%-91% and 77%-81%, respectively.

BRCA2 Mutation Ups Prostate Cancer Death Risk

In a study, the 12-year prostate cancer survival rate was 61.8% for men with the mutation versus 94.3% for those without it.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs